Regulating drugs, medical devices, and diagnostic tests in the European Union: early lessons from the COVID-19 pandemic?

Paper discusses what is being learned about conduct of clinical trials and EU systems for evaluating new drugs and devices, including are they ‘fit for purpose’ in responding to a major public health challenge, and how stakeholders should be contributing to regulatory governance.


European Heart Journal